{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:17:12Z","timestamp":1791476232870,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ccm.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T16:05:15Z","timestamp":1689696315000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of Mortality in Sarcoidosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Gamze","family":"K\u0131rk\u0131l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2023.06.006_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MCP.0000000000000080","article-title":"Morbidity and mortality in sarcoidosis","volume":"20","author":"Gerke","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2023.06.006_bib3","doi-asserted-by":"crossref","first-page":"1701815","DOI":"10.1183\/13993003.01815-2017","article-title":"Sarcoidosis mortality in Sweden: a population-based cohort study","volume":"51","author":"Rossides","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mayocp.2015.10.024","article-title":"Epidemiology of sarcoidosis 1946\u20132013: a population-based study","volume":"91","author":"Ungprasert","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ccm.2023.06.006_bib5","first-page":"217","article-title":"Sarcoidosis-related mortality and the impact of corticosteroid treatment: a population-based cohort study","volume":"27","author":"Sikj\u00e6r","year":"2022","journal-title":"Respir"},{"key":"10.1016\/j.ccm.2023.06.006_bib6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.rmed.2018.11.010","article-title":"Sarcoidosis deaths in the United States: 1999-2016","volume":"149","author":"Kearney","year":"2019","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.006_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"Mirsaeidi","year":"2015","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.006_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.006_bib10","first-page":"24","article-title":"The incidence, comorbidity and mortality of sarcoidosis in Korea, 2008-2015: a nationwide population-based study","volume":"37","author":"Jeon","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"11","key":"10.1016\/j.ccm.2023.06.006_bib11","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.006_bib12","first-page":"154","article-title":"Predicting respiratory failure in sarcoidosis patients","volume":"14","author":"Baughman","year":"1997","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib13","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1183\/09031936.00187410","article-title":"Stage IV sarcoidosis: comparison of survival with the general population and causes of death","volume":"38","author":"Nardi","year":"2011","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.006_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-9343(97)89518-6","article-title":"Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data","volume":"100","author":"Gideon","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","article-title":"Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization","volume":"145","author":"Rybicki","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ccm.2023.06.006_bib16","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib17","first-page":"128","article-title":"Mortality among african American women with sarcoidosis: data from the black women\u2019s health study","volume":"30","author":"Tukey","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1183\/13993003.00457-2016","article-title":"Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis","volume":"48","author":"Jamilloux","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1183\/09031936.93.06030349","article-title":"Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage","volume":"6","author":"Viskum","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5588\/ijtld.11.0077","article-title":"Mortality trends for tuberculosis and sarcoidosis in English populations, 1979\u20132008","volume":"16","author":"Duncan","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1136\/thx.2006.062836","article-title":"Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK","volume":"61","author":"Gribbin","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.06.006_bib22","doi-asserted-by":"crossref","first-page":"106828","DOI":"10.1016\/j.rmed.2022.106828","article-title":"Trends in sarcoidosis mortality rate in Japan from 2001 to 2020: a population-based study","volume":"196","author":"Harada","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib23","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1183\/13993003.00477-2016","article-title":"Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden","volume":"48","author":"Arkema","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib24","doi-asserted-by":"crossref","first-page":"e0176859","DOI":"10.1371\/journal.pone.0176859","article-title":"Sarcoidosis in an Italian province. Prevalence and environmental risk factors","volume":"12","author":"Deborah","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2023.06.006_bib25","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2019.03.048","article-title":"Disparities in sarcoidosis mortality by region, urbanization, and race in the United States: a multiple cause of death analysis","volume":"132","author":"Ogundipe","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib26","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1164\/rccm.201103-0409ED","article-title":"Who dies from sarcoidosis and why?","volume":"183","author":"Baughman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib27","first-page":"167","article-title":"Sarcoidosis: a long-term follow up study","volume":"17","author":"Chappell","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.chest.2016.01.020","article-title":"Association between occupational exposures and sarcoidosis: an analysis from death certificates in the United States, 1988\u20131999","volume":"151","author":"Liu","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.06.006_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1164\/rccm.200303-459OC","article-title":"Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients","volume":"169","author":"Grunewald","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1399-0039.2009.01437.x","article-title":"The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis","volume":"75","author":"Wijnen","year":"2010","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ccm.2023.06.006_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.humimm.2011.01.011","article-title":"Butyrophilin-like 2 in pulmonarysarcoidosis: a factor for susceptibility and progression?","volume":"72","author":"Wijnen","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.ccm.2023.06.006_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-0039.2010.01590.x","article-title":"Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis","volume":"77","author":"Heron","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ccm.2023.06.006_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1183\/09031936.00010209","article-title":"CARD15\/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis","volume":"35","author":"Sato","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1164\/rccm.200512-1839OC","article-title":"Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis","volume":"174","author":"Hill","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib35","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.129.6.1584","article-title":"Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis","volume":"129","author":"Kruit","year":"2006","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccm.2023.06.006_bib36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1378\/chest.115.4.1158","article-title":"An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment","volume":"115","author":"Judson","year":"1999","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.006_bib37","first-page":"123","article-title":"Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis","volume":"11","author":"Vestbo","year":"1994","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.ccm.2023.06.006_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2019.03.012","article-title":"Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis","volume":"152","author":"Judson","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000477736","article-title":"Increased risk of atherosclerosis in patients with sarcoidosis","volume":"84","author":"Bargagli","year":"2017","journal-title":"Pathobiology"},{"key":"10.1016\/j.ccm.2023.06.006_bib40","doi-asserted-by":"crossref","first-page":"1601290","DOI":"10.1183\/13993003.01290-2016","article-title":"Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976\u20132013","volume":"49","author":"Ungprasert","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00408-017-0076-4","article-title":"The burden of comorbidity and complexity in sarcoidosis: impact of associated chronic diseases","volume":"196","author":"Brito-Zeron","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.ccm.2023.06.006_bib42","first-page":"115","article-title":"What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis","volume":"32","author":"Martusewicz-Boros","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2018.10.004","article-title":"Sarcoidosis: a benign disease or a culture of neglect?","volume":"144","author":"Wells","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib44","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/crj.12398","article-title":"The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study","volume":"11","author":"Nowinski","year":"2017","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib45","first-page":"525","article-title":"Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients","volume":"52","author":"Neville","year":"1983","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1378\/chest.14-1475","article-title":"Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies","volume":"147","author":"Bonifazi","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.006_bib47","doi-asserted-by":"crossref","first-page":"e0151940","DOI":"10.1371\/journal.pone.0151940","article-title":"In-hospital disease burden of sarcoidosis in Switzerland from 2002 to 2012","volume":"11","author":"Pohle","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.006_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00408-019-00210-x","article-title":"Inpatient prevalence, expenditures, and comorbidities of sarcoidosis: nationwide inpatient sample 2013-2014","volume":"197","author":"Ungprasert","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.ccm.2023.06.006_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.rmed.2018.08.008","article-title":"Sarcoidosis and IPF in the same patient \u2013 a coincidence, an association or a phenotype?","volume":"144","author":"Collins","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MD.0b013e3182569f91","article-title":"Late-onset sarcoidosis: a comparative study","volume":"91","author":"Varron","year":"2012","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.ccm.2023.06.006_bib51","first-page":"227","article-title":"Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis","volume":"20","author":"Reich","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib53","doi-asserted-by":"crossref","first-page":"2000767","DOI":"10.1183\/13993003.00767-2020","article-title":"Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study","volume":"56","author":"Rossides","year":"2020","journal-title":"Eur Respir J"},{"issue":"Suppl-6","key":"10.1016\/j.ccm.2023.06.006_bib54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1513\/AnnalsATS.201707-566OT","article-title":"High-risk sarcoidosis current concepts and research imperatives","volume":"14","author":"Sauer","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2023.06.006_bib55","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.12688\/f1000research.20696.1","article-title":"Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns","volume":"8","author":"Judson","year":"2019","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.006_bib56","first-page":"27","article-title":"Presentation of sarcoidosis and outcome of pulmonary changes","volume":"29","author":"Romer","year":"1982","journal-title":"Dan Med Bull"},{"issue":"2","key":"10.1016\/j.ccm.2023.06.006_bib57","first-page":"158","article-title":"The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases","volume":"17","author":"Pietinalho","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.12703\/P6-89","article-title":"Advances in the diagnosis and treatment of sarcoidosis","volume":"6","author":"Judson","year":"2014","journal-title":"F1000prime reports"},{"key":"10.1016\/j.ccm.2023.06.006_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1378\/chest.121.1.32","article-title":"Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and cortico- steroid therapy","volume":"121","author":"Reich","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccm.2023.06.006_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.127.1.171","article-title":"Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis","volume":"127","author":"King","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2023.06.006_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/thoraxjnl-2015-207011","article-title":"Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity, analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis","volume":"71","author":"Nathan","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.06.006_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib64","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing & pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib65","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","article-title":"Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis","volume":"129","author":"Handa","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.06.006_bib66","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1183\/09031936.00175907","article-title":"Clinical predictors of pulmonary hypertension in sarcoidosis","volume":"32","author":"Bourbonnais","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib67","first-page":"82","article-title":"Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies","volume":"31","author":"Keir","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clim.2018.12.012","article-title":"The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension-a cohort study","volume":"199","author":"Tiosano","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ccm.2023.06.006_bib69","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00897-2019","article-title":"Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study","volume":"54","author":"Huitema","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib70","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0012-3692(15)37649-2","article-title":"Predicting mortality in patients with sarcoidosis awaiting lung transplantation","volume":"124","author":"Shorr","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.06.006_bib71","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1378\/chest.120.3.873","article-title":"Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation","volume":"120","author":"Arcasoy","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.06.006_bib72","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.06.006_bib73","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1038\/s41598-019-40030-w","article-title":"Clinical features and outcomes of patients & with sarcoidosis-associated pulmonary hypertension","volume":"9","author":"Parikh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ccm.2023.06.006_bib74","first-page":"184","article-title":"Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension","volume":"37","author":"Abston","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"S1","key":"10.1016\/j.ccm.2023.06.006_bib75","first-page":"155","article-title":"Sarcoidosis at mount sinai medical center New York, 1981\u2013 1985","volume":"9","author":"Teirstein","year":"1992","journal-title":"Sarcoidosis"},{"key":"10.1016\/j.ccm.2023.06.006_bib76","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations","volume":"119","author":"Perry","year":"1995","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ccm.2023.06.006_bib77","first-page":"285","article-title":"The frequency of diastolic dysfunction in patients with sarcoidosis and it\u2019s relationship with HLA DRB1 alleles","volume":"36","author":"\u00d6zyilmaz","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.06.006_bib78","doi-asserted-by":"crossref","first-page":"e007844","DOI":"10.1161\/JAHA.117.007844","article-title":"Hospitalization rates, prevalence of cardio vascular manifestations, and outcomes associated with sarcoidosis in the United States","volume":"7","author":"Patel","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ccm.2023.06.006_bib79","first-page":"372","article-title":"Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan","volume":"43","author":"Iwai","year":"1993","journal-title":"Acta Pathol"},{"key":"10.1016\/j.ccm.2023.06.006_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2008.09.009","article-title":"Cardiac sarcoidosis","volume":"157","author":"Kim","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccm.2023.06.006_bib81","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/01.CIR.58.6.1204","article-title":"Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis","volume":"58","author":"Silverman","year":"1978","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2023.06.006_bib82","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccm.2023.06.006_bib83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/pace.12277","article-title":"Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia","volume":"37","author":"Nery","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.ccm.2023.06.006_bib84","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/thx.2010.134429","article-title":"Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study","volume":"66","author":"Crawshaw","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.06.006_bib85","article-title":"National temporal trends in hospitalization and inpatient mortality in patients with pulmonary sarcoidosis in the United States between 2007 \u2013 2018","author":"Alqalyoobi","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.06.006_bib86","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1183\/09031936.00226911","article-title":"Global burden of chronic pulmonary aspergillosis complicating sarcoidosis","volume":"41","author":"Denning","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.06.006_bib87","doi-asserted-by":"crossref","first-page":"1602396","DOI":"10.1183\/13993003.02396-2016","article-title":"Chronic pulmonary aspergillosis complicating sarcoidosis","volume":"49","author":"Uzunhan","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:16:33Z","timestamp":1759454193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523123000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0272523123000473"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2023.06.006","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Mortality in Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}